Evidence map›Paper›PMID 37477130›Full record

ArticleInternational journal of molecular medicine2023

Effects of Sulforaphane on SARS‑CoV‑2 infection and NF‑κB dependent expression of genes involved in the COVID‑19 'cytokine storm'.

Jessica Gasparello, Giovanni Marzaro, Chiara Papi, Valentina Gentili, Roberta Rizzo, Matteo Zurlo, Chiara Scapoli, Alessia Finotti, Roberto Gambari

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jessica GasparelloDepartment of Life Sciences and Biotechnology, University of Ferrara, I‑44121 Ferrara, Italy.
Giovanni MarzaroDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, I‑35131 Padova, Italy.
Chiara PapiDepartment of Life Sciences and Biotechnology, University of Ferrara, I‑44121 Ferrara, Italy.
Valentina GentiliDepartment of Chemical and Pharmaceutical Sciences, University of Ferrara, I‑44121 Ferrara, Italy.
Roberta RizzoDepartment of Chemical and Pharmaceutical Sciences, University of Ferrara, I‑44121 Ferrara, Italy.
Matteo ZurloDepartment of Life Sciences and Biotechnology, University of Ferrara, I‑44121 Ferrara, Italy.
Chiara ScapoliDepartment of Life Sciences and Biotechnology, University of Ferrara, I‑44121 Ferrara, Italy.
Alessia FinottiDepartment of Life Sciences and Biotechnology, University of Ferrara, I‑44121 Ferrara, Italy.
Roberto GambariDepartment of Life Sciences and Biotechnology, University of Ferrara, I‑44121 Ferrara, Italy.
University of Ferrara · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since its spread at the beginning of 2020, the coronavirus disease 2019 (COVID‑19) pandemic represents one of the major health problems. Despite the approval, testing, and worldwide distribution of anti‑severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) vaccines, the development of specific antiviral agents targeting the SARS‑CoV‑2 life cycle with high efficiency, and/or interfering with the associated 'cytokine storm', is highly required. A recent study, conducted by the authors' group indicated that sulforaphane (SFN) inhibits the expression of IL‑6 and IL‑8 genes induced by the treatment of IB3‑1 bronchial cells with a recombinant spike protein of SARS‑CoV‑2. In the present study, the ability of SFN to inhibit SARS‑CoV‑2 replication and the expression of pro‑inflammatory genes encoding proteins of the COVID‑19 'cytokine storm' was evaluated. SARS‑CoV‑2 replication was assessed in bronchial epithelial Calu‑3 cells. Moreover, SARS‑CoV‑2 replication and expression of pro‑inflammatory genes was evaluated by reverse transcription quantitative droplet digital PCR. The effects on the expression levels of NF‑κB were assessed by western blotting. Molecular dynamics simulations of NF‑kB/SFN interactions were conducted with Gromacs 2021.1 software under the Martini 2 CG force field. Computational studies indicated that i) SFN was stably bound with the NF‑κB monomer; ii) a ternary NF‑kB/SFN/DNA complex was formed; iii) the SFN interacted with both the protein and the nucleic acid molecules modifying the binding mode of the latter, and impairing the full interaction between the NF‑κB protein and the DNA molecule. This finally stabilized the inactive complex. Molecular studies demonstrated that SFN i) inhibits the SARS‑CoV‑2 replication in infected Calu‑3 cells, decreasing the production of the N‑protein coding RNA sequences, ii) decreased NF‑κB content in SARS‑CoV‑2 infected cells and inhibited the expression of NF‑kB‑dependent IL‑1β and IL‑8 gene expression. The data obtained in the present study demonstrated inhibitory effects of SFN on the SARS‑CoV‑2 life cycle and on the expression levels of the pro‑inflammatory genes, sustaining the possible use of SFN in the management of patients with COVID‑19.

Indexed as

COVID-19DNAHumansInterleukin-8IsothiocyanatesNF-kappa BSARS-CoV-2SulfoxidesDNAInterleukin-8IsothiocyanatesNF-kappa BsulforaphaneSulfoxidesCOVID‑19NF‑kBnutraceuticalspro‑inflammatory genesSARS‑CoV‑2SFN

Identifiers

PMID37477130
PMCPMC10555481
OpenAlexW4384298549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.